2008. Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance. BMJ, 336, 1246-1248.Cooper A, O'Flynn N. Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE ...
Cardiovascular disease (CVD) is the leading cause of death inEngland and Wales, accounting for almost a third of deaths. Anupdate of existing National Institute for Health and CareExcellence (NICE) guidance (published in 2008)1 was necessaryin light of new evidence on the efficacy and safety ...
et al. The association between the stress hyperglycaemia ratio and mortality in cardiovascular disease: a meta-analysis and systematic review. Cardiovasc Diabetol 23, 412 (2024). https://doi.org/10.1186/s12933-024-02454-1 Download citation Received29 July 2024 Accepted24 September 2024 Published16...
The aim of the 2012 guidelines from the Fifth Joint Task Force (JTF) of the European Societies on Cardiovascular Disease Prevention in Clinical Practice is to give an update of the present knowledge in preventive cardiology for physicians and other health workers. The document differs from 2007 gu...
outcomes in patients with T2DM and kidney disease irrespective of HbA1c levels or insulin use [101]. Therefore, finerenone should be considered for treatment of patients with T2DM, and this agent is likely to be included as an important treatment option in future updates of current guidelines....
In this multi-center prospective study, we aimed to determine the association between antiphospholipid antibodies (aPLs) and future atherosclerotic cardiovascular disease (ASCVD) in SLE. Methods In total, 1573 SLE patients were recruited based on the Chinese SLE Treatment and Research group (CSTAR) ...
Prevention of cardiovascular disease in T2DM Individualized glycemic management in patients with T2DM and CVD Glycemic targets Current recommendations on the use of antidiabetic drugs with regard to CVD Hypertension Lipid management Antiplatelet therapy Conclusion Availability of data and materials Abbreviations...
Clinical Guidelines and Evidence Review for Lipid Modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease Cooper A and O'Flynn N. Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE gui...
European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts...
The 3rd Cardiovascular Outcome Trial Summit of the Diabetes & Cardiovascular Disease EASD Study Group was held on the 26–27 October 2017 in Munich. As in 2015 and 2016, this summit was organised in light of recently completed and published CVOTs on diabetes, aiming to serve as a reference ...